Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

NCT07441174 is registered in ClinicalTrials.gov with InxMed (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07441174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07441174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase Ib/II Clinical Trial of IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 28, 2026
Completion date
February 28, 2031
Enrollment
92 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

pdac, solid tumor cancer